Citadel Advisors’s Champions Oncology CSBR Stock Holding History

Citadel Advisors’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,100	Closed	-$18.2K	–	12881
2025 Q1	$18.2K	Buy	2,100 +1,100	+110%	+$11.1K	﹤0.01%	13214
2024 Q4	$8.57K	Buy	+1,000	New	+$5.03K	﹤0.01%	13677
2024 Q3	–	Sell	-6,100	Closed	-$31.5K	–	14355
2024 Q2	$31.5K	Sell	6,100 -3,100	-34%	-$15.1K	﹤0.01%	12214
2024 Q1	$45.1K	Sell	9,200 -500	-5%	-$2.93K	﹤0.01%	12263
2023 Q4	$52.5K	Buy	9,700 +5,100	+111%	+$28.4K	﹤0.01%	11735
2023 Q3	$28.6K	Sell	4,600 -75,000	-94%	-$474K	﹤0.01%	12309
2023 Q2	$501K	Buy	79,600 +71,300	+859%	+$368K	﹤0.01%	7940
2023 Q1	$33.4K	Buy	8,300 +2,800	+51%	+$12K	﹤0.01%	12625
2022 Q4	$24.8K	Sell	5,500 -15,700	-74%	-$103K	﹤0.01%	12953
2022 Q3	$159K	Buy	+21,200	New	+$177K	﹤0.01%	10641

Other funds holding CSBR

BMC

Battery Management Corp Boston, Massachusetts $368M AUM 28.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's CSBR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Champions Oncology (CSBR) in Q2 2026: 18,295 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #12602 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CSBR as recently as Q3 2025.

Citadel Advisors first reported a position in CSBR in Q3 2016 and has held it in 15 quarters since. The position peaked at $280K in Q3 2022. 28 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.

Citadel Advisors held 18,295 shares of Champions Oncology worth $113K as of Q2 2026.
Champions Oncology was a new Citadel Advisors position in Q2 2026.
Champions Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12602 holding.
Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and has held it in 15 quarters since.
Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
28 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.